Skip to main content

Advertisement

SpringerLink
Log in

Antiangiogenic Treatment of Meningiomas

  • Neuro-oncology (R Soffietti, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Meningiomas are the most common intracranial tumors and the majority of cases is curable by surgical resection. Incompletely resected tumors and tumors with signs of increased malignancy (WHO grade II and III tumors) are prone to recur. In meningiomas relapsing after surgical resection and after exhaustion of radiotherapeutic options, drug therapy is to be considered. A variety of drugs has been studied in meningiomas, including hydroxyurea, temozolomide, irinotecan, interferon-alpha, mifepristone, octreotide analogues, megestrol acetate, bevacizumab, sunitinib, vatalinib, imatinib, erlotinib, and gefitinib. Unfortunately, most of these agents have shown no or very limited activity against meningiomas and cannot be recommended for clinical use. Compounds with antiangiogenic properties, i.e., bevacizumab, sunitinib, and vatalinib have shown potential efficacy in uncontrolled studies and should be investigated further, ideally in randomized clinical trials. Emerging clinical studies will evaluate novel medical treatment approaches including the tetra-hydroisoquinoline alkaloid trabectedin (European Organisation for Research and Treatment of Cancer (EORTC) phase II trial 1320) and SMO or AKT inhibitors in molecularly selected cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95(3):401–11.

    Article  PubMed  Google Scholar 

  2. Woehrer A, Hackl M, Waldhor T, Weis S, Pichler J, Olschowski A, et al. Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry. Br J Cancer. 2014;110(2):286–96.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829–40. Thorough review and evaluation of published studies on drug therapy of meningiomas including definition of benchmark efficacy endpoints.

    Article  PubMed  Google Scholar 

  4. Baumgarten P, Brokinkel B, Zinke J, Zachskorn C, Ebel H, Albert FK, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol. 2013;28(9):1157–66.

    PubMed  Google Scholar 

  5. Nassehi D, Dyrbye H, Andresen M, Thomsen C, Juhler M, Laursen H, et al. Vascular endothelial growth factor a protein level and gene expression in intracranial meningiomas with brain edema. APMIS. 2011;119(12):831–43.

    Article  PubMed  Google Scholar 

  6. Preusser M, Hassler M, Birner P, Rudas M, Acker T, Plate KH, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of antiangiogenic therapy approaches. Clin Neuropathol. 2012;31(5):352–60.

    Article  PubMed  Google Scholar 

  7. Preusser M, Berghoff AS, Hottinger AF. High-grade meningiomas: new avenues for drug treatment? Curr Opin Neurol. 2013;26(6):708–15.

    Article  CAS  PubMed  Google Scholar 

  8. Preusser M, Spiegl-Kreinecker S, Lotsch D, Wohrer A, Schmook M, Dieckmann K, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. 2012;118(20):5038–49.

    Article  CAS  PubMed  Google Scholar 

  9. Sahm F, Bissel J, Koelsche C, Schweizer L, Capper D, Reuss D, et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol. 2013;126(5):757–62.

    Article  CAS  PubMed  Google Scholar 

  10. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285–9. Identification of oncogenic mutations with potential relevance as drug targets in meningiomas.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077–80. Identification of oncogenic mutations with potential relevance as drug targets in meningiomas.

    Article  CAS  PubMed  Google Scholar 

  12. Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117(1):93–101. Clinical study reporting potential activity of vatalanib.

    Article  CAS  PubMed  Google Scholar 

  13. Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116–21. Clinical study reporting potential activity of sunitinib.

    Article  PubMed  Google Scholar 

  14. Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70. Restrospective study reporting potential activity of bevacizumab.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93. Retrospective study reporting potential activity of bevacizumab.

    Article  CAS  PubMed  Google Scholar 

  16. Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013;8(3), e59941.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21(12):2445–6.

    Article  CAS  PubMed  Google Scholar 

  18. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015;17(4):488–504.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Matthias Preusser declares the receipt of honoraria, research support (unrestricted grants), and travel support (scientific meetings) from Roche, GlaxoSmithKline, Böhringer-Ingelheim, and Bristol-Myers Squibb.

Christine Marosi declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Department of Medicine I Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Matthias Preusser MD & Christine Marosi MD

Authors
  1. Matthias Preusser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Marosi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Preusser MD.

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Preusser, M., Marosi, C. Antiangiogenic Treatment of Meningiomas. Curr Treat Options Neurol 17, 29 (2015). https://doi.org/10.1007/s11940-015-0359-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-015-0359-0

Keywords

Search

Navigation